Company: MYGN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0000899923-25-000112
Chunk: 16

Company: MYRIAD GENETICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
Item 1.    Financial Statements.

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (unaudited)

(in millions)

September 30,2025December 31,2024ASSETSCurrent assets:Cash and cash equivalents$145.4 $102.4 Trade accounts receivable118.0 121.2 Inventory31.6 27.5 Prepaid taxes13.8 16.4 Prepaid expenses and other current assets36.0 30.5 Total current assets344.8 298.0 Operating lease right-of-use assets50.6 55.0 Property, plant, and equipment, net111.4 117.4 Intangibles, net163.1 262.4 Goodwill51.6 286.3 Other assets6.6 8.5 Total assets$728.1 $1,027.6 LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$31.8 $32.3 Accrued liabilities108.3 119.0 Current maturities of operating lease liabilities7.9 12.8 Total current liabilities148.0 164.1 Unrecognized tax benefits1.2 32.7 Long-term debt119.5 39.6 Noncurrent operating lease liabilities84.9 87.9 Other long-term liabilities1.7 2.2 Total liabilities355.3 326.5 Commitments and contingenciesStockholders’ equity:Common stock, 93.1 and 91.3 shares outstanding at September 30, 2025 and December 31, 2024, respectively0.9 0.9 Additional paid-in capital1,486.8 1,457.8 Accumulated other comprehensive loss(0.1)(0.8)Accumulated deficit(1,114.8)(756.8)Total stockholders' equity372.8 701.1 Total liabilities and stockholders’ equity$728.1 $1,027.6 

See accompanying notes to Condensed Consolidated Financial Statements.

4

Table of Contents

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (unaudited)

(in millions, except per share amounts)